HIV in pregnancy
Bictegravir-containing antiretroviral therapy (ART) now recommended as preferred option for pregnant women
The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission has updated its recommendations for the use of ART in pregnant women.
Bictegravir plus tenofovir alafenamide plus emtricitabine (available as a fixed-dose combination formulation) is now recommended as a preferred option for the treatment of HIV during pregnancy (or when trying to conceive). The regimen is recommended in treatment-naive pregnant women, provided that long-acting cabotegravir has not been used previously for pre-exposure prophylaxis (PrEP). This regimen was previously recommended as an alternative ART regimen.
Bictegravir, an integrase strand transfer inhibitor (INSTI), is associated with high rates of viral suppression, and is well tolerated. Birth outcomes have been reassuring based on cohort studies in the US.
The Panel continues to recommend dolutegravir plus a tenofovir-containing dual-nucleoside reverse transcriptase inhibitor (NRTI) combination as another preferred option in pregnant women.
Summary
Definition
História e exame físico
Principais fatores diagnósticos
- increased risk of maternal HIV acquisition
- increased risk of perinatal HIV transmission
Outros fatores diagnósticos
- oral candidiasis
- increasing dyspnea
- weight loss
- fever
- malaise
- lymphadenopathy
- maculopapular blanching rash
Fatores de risco
- people who inject drugs
- unprotected penile-vaginal intercourse
- unprotected anal intercourse
- percutaneous needle stick injury
- coinfection with other sexually transmitted infections (STIs) or bacterial vaginosis
- high maternal viral load (perinatal transmission)
- absence of prenatal maternal antiretroviral therapy (perinatal transmission)
- breast-feeding in mothers without viral suppression (perinatal transmission)
- violence against women and girls
- receptive oral intercourse
- insertive oral intercourse
- multiple sexual partners
- low maternal CD4 count (perinatal transmission)
- cosmetic injection procedures
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- maternal HIV-1/HIV-2 antigen/antibody enzyme-linked immunosorbent assay (ELISA)
- maternal HIV-1/HIV-2 antibody differentiation immunoassay
- infant HIV DNA or RNA polymerase chain reaction (PCR)
Investigações a serem consideradas
- HIV-1 western blot
- HIV-1 indirect immunofluorescence assay (IFA)
- HIV-1 nucleic acid test (NAT)
- CD4 count
- plasma HIV RNA levels (viral load)
- renal function tests
- liver function tests (LFTs)
- drug resistance tests
- complete blood count
- glucose screening
- fetal ultrasound
- tests for coinfections
Algoritmo de tratamento
pregnant women: <38 weeks not in labor (regardless of HIV RNA level)
pregnant women with HIV RNA levels >1000 copies/mL: at 38 weeks or in labor
pregnant women with HIV RNA levels ≤1000 copies/mL: at 38 weeks or in labor
infant with in utero or intrapartum HIV exposure
Colaboradores
Autores
Anna Powell, MD
Assistant Professor
Johns Hopkins University School of Medicine
Gynecology and Obstetrics
Baltimore
MD
Declarações
AP declares that she has been paid for consultancy work with Cepheid in the past and receives royalties for authorship from UpToDate.
Agradecimentos
Dr Anna Powell would like to gratefully acknowledge Dr Rachel K. Scott, Dr Isaac Delke, Dr Christina Bailey, and Dr Mettassebia Kano, the previous contributors to this topic.
Declarações
RKS declares that she has participated in an advisory meeting for ViiV Healthcare and has received research funding from ViiV, managed by MedStar Health Institute. ID, CB, and MK declare that they have no competing interests.
Revisores
Aisha Sethi, MD
Assistant Professor of Medicine
Associate Residency Program Director
University of Chicago
Chicago
IL
Declarações
AS declares that she has no competing interests.
Graham P. Taylor, MBChB, FRCP, FHEA
Reader in Communicable Diseases
Faculty of Medicine
Imperial College
London
UK
Declarações
GPT has been reimbursed by various pharmaceutical companies for attending conferences, lecturing, and consulting, and has been chief investigator of investigator-initiated industry-funded research on HIV and pregnancy.
Créditos aos pareceristas
Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.
Declarações
As afiliações e declarações dos pareceristas referem--se ao momento da revisão.
Referências
Principais artigos
Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. Jun 2025 [internet publication].Texto completo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
Diagnósticos diferenciais
- Infectious mononucleosis
- Toxoplasmosis
- Viral hepatitis
Mais Diagnósticos diferenciaisDiretrizes
- Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States
- CDC Yellow Book: health information for international travel - travelers with HIV
Mais DiretrizesFolhetos informativos para os pacientes
HIV infection in pregnancy
Mais Folhetos informativos para os pacientes
Conectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal